Key result
Milvexian shows dose-dependent VTE prevention without increasing bleeding risk in phase II trials.
Why the study?
Direct oral anticoagulants have a dose-dependent increased bleeding risk that limits their use in certain populations, creating an unmet clinical need.
Design
Review
Authors
Loading...
Supports pursuit of factor XIa inhibition as a potentially safer strategy; leaves open net clinical benefit pending phase III confirmation.
Milvexian is an emerging oral factor XIa inhibitor that may offer effective anticoagulation without the dose-dependent bleeding risks associated with current direct oral anticoagulants.
Parsa et al. (2024) conducted a review in Thromboembolism. Milvexian was evaluated. Milvexian, an oral factor XIa inhibitor, demonstrated dose-dependent prevention of venous thromboembolism without increasing bleeding risk in phase II trials, supporting its ongoing evaluation in large-scale phase III trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: